(Medicine label) Medicine label Extract 1 COUGH FORMULA Contains Dextromethorphan, a cough suppressant as effective as codeine, but not narcotic Dosage: Adults: Two teaspoons every 8 hours. Not to exceed 6 teaspoons a day. Children : 6 to 12 years-one teaspoon every 8 hours. Not to exceed 3 teaspoons a day CAUTION - A persistent cough may be a sign of a serious condition
American people can buy antibiotics in Australia online here: https://buyantibiotics-24h.com/ No prescription required and cheap price!
On behalf of the german society of neurology (dgn) we developed guidelines on neurogenic dysphagia (nd), which were accepted iGuidelines of the German Society of Neurology (DGN) on Neurogenic Dysphagia (ND)
Neurologisches Krankenhaus München (NKM), Tristanstr. 20, D-80804 Munich, Germany The abovementioned guidelines were accepted by the DGN guidelines commission in September 2004 and will be published by the DGN in 2005. The main recommendations of these guidelines are as follows: ! Diagnosis of ND is possible in most cases by accurate history taking and neurological examination. If the etiology of ND is unknown, a checking list may be of value (see below), in order not to forget any cause. ! For bedside screening examination we recommend the 50-ml water test combined with assessment of pharyngeal sensibility or with pulse oximetry. ! Concerning the monitoring of swallowing therapy, the diagnostic expressiveness of videofluoroscopic swallowing study (VFFS) and fiberoptic endoscopic evaluation of swallowing (FEES) is probably equivalent. At least in the beginning of swallowing therapy, VFSS should be performed in order to reveal (frequent) dysfunctions of the upper esophageal sphincter (UES) which cannot be seen by FEES. ! With regard to VFSS we recommend a training period of at least ½ year in about 300 patients under supervision of an experienced radiologist. In Germany, only phoniatrists are obliged to study FEES so that other professions need to see to their own further education themselves. ! Important sequelae of ND, which should be avoided or minimized by special penetration/aspiration, aspiration pneumonia, dependence on tube feeding and/or tracheal cannula, high health care costs, reduced quality of life and death. ! L-dopa, amantadine or ACE inhibitors may be applied in certain cases, since they might elicit the swallowing reflex or are protective against aspiration pneumonias. Study results are, however, contradictory. ! Many disturbances which occur in association with ND can be treated pharmacologically very successfully, e.g hiccup with a combination of baclofen, domperidone and a proton pump inhibitor (Gabapentin may be added in severe cases); gastroesophageal reflux disease (GERD) should be treated with proton pump inhibitors, since GERD may aggravate a preexisting ND. ! Oral hygiene of the patients and hand desinfection of the people handling them seem to be effective interventions against aspiration pneumonia in ND patients. ! The prerequisites for cricopharyngeal myotomy in cases of UES dysfunction are: normal elevation of hyoid and larynx, non-successful swallowing therapy in achieving the opening of the UES and pharyngeal pressure sufficient to propel a bolus through the UES. Therefore, manofluoroscopy is necessary prior to these procedures. The same prerequisites hold true for Botulinum toxin injection of the UES as an alternative method. Balloon catheter dilatation of the UES cannot be generally recommended for lack of study results and small examined patient numbers. ! If tube feeding is indicated in acute neurological diseases such as stroke, nasogastral tube feeding seems to be superior to feeding via percutaneous endoscopic gastrostomy (PEG) within the first month. In longlasting ND (> 1 month) PEG feeding is the treatment of choice; in progressive diseases such as amyotrophic lateral sclerosis, PEG should be performed before forced vital capacity (fVC) is less than 50-60%; in the latter case PEG should be performed using noninvasive positive pressure ventilation, oxygen support and conscious sedation; an alternative is percutaneous radiological gastrostomy (PRG). ! In cases with trachetomy and a blocked cuff, intermittent subglottic secretion drainage seems to be an effective intervention for aspiration pneumonia. ! Patients with a dilatative tracheostomy should neither be admitted into rehab units or nursing homes nor be discharged home without trained personell. ! There are many effective methods of functional swallowing therapy. The efficacy of restitutional methods has not yet sufficiently been investigated. Compensatory methods (postural changes and swallowing techniques/maneuvers) are effective depending on the dysphagic disturbance pattern. Dietary modification such as thickening of liquids are effective, provided that their effect is controlled by use of VFSS and/or FEES. ! Faciooral tract therapy (F.O.T.T.), which may also be performed in uncooperative or unconscious patients with ND, is an empirical therapy, but cannot be recommended for lack of evidence-based results regarding efficacy. Checking list in cases of unknown etiology of neurogenic dysphagia Electromyography (EMG), repetitive nerve stimulation Critical illness polyneuropathy/myopathy (CIP/CIM), acute inflammatory demyelinating polyneuritis (AIDP)/acute Guillain-Barré syndrome (aGBS), myotonic dystrophies, myasthenia gravis, Lambert-Eaton myasthenic syndrome (LEMS) Multiple sclerosis (MS), brainstem diseases, multisystem atrophies (MSA), Chiari malformation Acetylcholine receptor (AChR) Ab; muscle-specific tyrosine kinase (MuSK) antibodies Myositis-specific auto-Ab; anti-Jo-1-auto-Ab Polymyositis (PM), dermatomyosistis (DM), inclusion body myositis (IBM); anti-Jo-1 syndrome anti-dsDNA/ribosomal P Ab; anti-SS-A/Ro/SS-B/LA Ab; Systemic lupus erythematodes (SLE); Sjögren´s myositis-specific Ab; anti-Scl-70 Ab, anti-Centromer Ab; syndrome (SS); PM/DM/(IBM); systemic sclerosis (SSc); mixed connective tissue disease (MCTD) Antineutrophil cytoplasmic antibodies (ANCAs), HBSAG: c-ANCA (proteinase 3 [PR3]), p-ANCA (myeloperoxidase Wegener's granulomatosis (c-ANCA); microscopic [MPO]), anti-endothelial cell antibodies (AECA), HBSAG polyangiitis (p-ANCA); classic polyarteriitis Variants of Guillain-Barre syndrome (GBS): Polyneuritis cranialis; Miller Fisher syndrome CADASIL (Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy) (granular osmophilic material [GOM] in arterial walls) MSA, progressive supranuclear palsy (PSP) CADASIL, spinobulbar muscle atrophy (SBMA; Kennedy´s disease), oculopharyngeal muscle dystrophy (OPMD)
An Overview of Setting Occupational Exposure Limits (OELs) for Pharmaceuticals Robert H. Ku, Ph.D., CIH, Principal Toxicologist [Published in Chemical Health & Safety , January/February 2000] Setting appropriate occupational exposure limits is an integral component in assuring the health and safety of workers Introduction Occupational exposure limits (OELs) 1 for the pro